Login / Signup

Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience.

Behzad FatemiSoheila RezaeiSaeed TaheriFarzad Peiravian
Published in: Expert review of pharmacoeconomics & outcomes research (2020)
TFC was found to be cost-effective in patients with severe RA who do not respond well to methotrexate compared to ADA, ETN in Iran.
Keyphrases
  • rheumatoid arthritis
  • disease activity
  • ankylosing spondylitis
  • early onset
  • interstitial lung disease
  • juvenile idiopathic arthritis
  • rheumatoid arthritis patients
  • drug induced
  • replacement therapy
  • smoking cessation